How Cannabis Makes THC: Scientists Decode the Ancient Origins of Cannabinoids
Advertisement
For centuries, humans have known that cannabis produces compounds powerful enough to alter consciousness, relieve pain, and reduce inflammation. But the question of how — the molecular machinery that allows a plant to synthesize THC, CBD, CBC, and over a hundred other cannabinoids — has remained only partially understood. Now, a team of researchers at Wageningen University & Research in the Netherlands has pulled off something remarkable: they've resurrected the ancient enzymes that cannabis's ancestors used millions of years ago, experimentally demonstrating for the first time how the plant acquired its ability to produce cannabinoids.
The findings, published in Plant Biotechnology Journal, could reshape how medicinal cannabis is grown and how cannabinoids are produced for pharmaceutical use.
Key Takeaways
- Wageningen University scientists resurrected ancient cannabis enzymes using ancestral sequence reconstruction, revealing how THC, CBD, and CBC production evolved from a single generalist enzyme
- The ancestral enzymes proved more robust and flexible than modern versions, making them promising candidates for biotechnological cannabinoid production
- An ancestral enzyme that preferentially produces CBC could enable the first high-CBC cannabis cultivars — opening new possibilities for medicinal cannabis
Table of Contents
- The Evolutionary Puzzle: One Enzyme Becomes Three
- Resurrecting Ancient Enzymes
- Why Ancient Enzymes Could Be Better Than Modern Ones
- The CBC Opportunity: A Cannabinoid Without a Source
- How Cannabinoid Biosynthesis Actually Works
- What This Means for the Future of Cannabis
The Evolutionary Puzzle: One Enzyme Becomes Three
To understand what the Wageningen team accomplished, it helps to know how modern cannabis plants produce cannabinoids.
In today's cannabis, three specialized enzymes do the heavy lifting. THCA [Quick Definition: THC-acid — a non-psychoactive precursor that converts to THC when heated] synthase converts a precursor molecule called CBGA into THCA (which becomes THC when heated). CBDA synthase converts that same precursor into CBDA (the raw form of CBD).
And CBCA synthase produces CBCA, the precursor to CBC — a lesser-known cannabinoid with anti-inflammatory properties.
These three enzymes are remarkably similar in their molecular structure, differing by only a handful of amino acids. Scientists have long hypothesized that they evolved from a single ancestral enzyme through gene duplication — a process where a section of DNA is copied, and the two copies gradually specialize to perform different functions. But no one had experimentally proven this or characterized what those ancestral enzymes actually looked like.
That's exactly what Robin van Velzen and Cloé Villard set out to do. Using a technique called ancestral sequence reconstruction, they analyzed DNA from modern cannabis plants to computationally infer the amino acid sequences of enzymes that existed millions of years ago. Then — and this is the remarkable part — they actually built those ancient enzymes in the laboratory and tested them.
Resurrecting Ancient Enzymes
The results were striking. The reconstructed ancestral enzymes turned out to be generalists — capable of producing multiple cannabinoids simultaneously, rather than specializing in just one. Where modern THCA synthase is finely tuned to produce primarily THCA, the ancestral version could churn out THCA, CBDA, and CBCA all at once, albeit less efficiently for any single product.
This finding supports the gene duplication hypothesis elegantly. Cannabis's evolutionary history appears to have followed a classic pattern: an ancestral gene encoding a flexible, multi-purpose enzyme was duplicated multiple times. Over millions of years, each copy accumulated mutations that sharpened its specificity — one becoming THCA synthase, another becoming CBDA synthase, and a third becoming CBCA synthase.
But the most surprising discovery wasn't about specialization — it was about robustness. The ancient enzymes proved to be "more robust and flexible than their descendants," according to van Velzen. In practical terms, this means the resurrected ancestral enzymes are hardier, more tolerant of varying conditions, and potentially more useful for biotechnological applications than the modern versions that cannabis plants use today.
Why Ancient Enzymes Could Be Better Than Modern Ones
This robustness finding has significant implications for the emerging field of cannabinoid biotechnology.
Currently, most cannabinoids are extracted directly from cannabis plants — a process that is land-intensive, water-intensive, and subject to all the variability that comes with agriculture. An alternative approach that is gaining traction involves using engineered microorganisms (like yeast or bacteria) to produce cannabinoids through fermentation, similar to how insulin or beer is made.
The challenge with microbial production has been getting the enzymes to work efficiently outside their native plant environment. Modern cannabis enzymes evolved to function within the specific cellular context of a cannabis trichome — the tiny resin glands on the plant's surface. When placed in a yeast cell or a bacterial system, these enzymes often perform poorly.
Ancestral enzymes, with their greater flexibility and robustness, could be better suited for these alternative production systems. Their tolerance for varying conditions means they might function more reliably in the foreign environment of a microbial host, potentially making biotechnological cannabinoid production more practical and cost-effective.
The CBC Opportunity: A Cannabinoid Without a Source
One of the most exciting implications of the research involves CBC (cannabichromene). Despite its demonstrated anti-inflammatory, anti-tumor, and neuroprotective properties, CBC has remained a minor player in the cannabis market for a simple reason: no naturally occurring cannabis strains produce it in meaningful quantities.
Modern cannabis cultivars are bred primarily for high THC content (recreational) or high CBD content (medical/wellness). CBC-dominant strains don't exist in commercial cultivation, making it expensive and impractical to produce CBC at scale through traditional extraction.
Van Velzen's team identified an ancestral "evolutionary intermediate" — an enzyme that preferentially produces CBCA, the precursor to CBC. As van Velzen notes, "Introducing this enzyme into a cannabis plant could lead to innovative medicinal varieties" — specifically, strains bred to produce high levels of CBC without the genetic and breeding obstacles that have so far prevented their development.
This approach could open a new frontier in medicinal cannabis. Instead of spending decades crossbreeding plants in hopes of stumbling on a high-CBC phenotype, breeders could use the ancestral enzyme as a genetic tool to deliberately create CBC-dominant cultivars.
How Cannabinoid Biosynthesis Actually Works
For readers curious about the full biochemical pathway, here's a simplified walkthrough of how cannabis makes its signature compounds.
It all starts with two precursor molecules: olivetolic acid (produced through the polyketide pathway) and geranyl pyrophosphate (from the terpene pathway). An enzyme called CBGA synthase combines these two precursors into CBGA — cannabigerolic acid — which is sometimes called the "mother cannabinoid" because it's the starting material for all other cannabinoids.
From CBGA, the pathway branches. THCA synthase converts CBGA to THCA. CBDA synthase converts it to CBDA.
CBCA synthase converts it to CBCA. Each of these acid forms is then converted to its more familiar neutral form — THC, CBD, or CBC — through decarboxylation [Quick Definition: Heating cannabis to activate THC and other cannabinoids], which happens when the plant material is heated (such as when smoked, vaped, or baked into edibles).
The ratio of these compounds in any given cannabis plant depends on which synthase enzymes are present and how active they are — which is ultimately determined by the plant's genetics. This is why THC-dominant strains, CBD-dominant strains, and balanced strains exist: they carry different versions and expression levels of these key enzymes.
Understanding this pathway at the ancestral level adds a new dimension. It suggests that the earliest cannabis plants produced a more diverse cocktail of cannabinoids, and that the dominance of THC in modern strains is partly a result of human selective breeding that has emphasized one branch of the pathway at the expense of others.
What This Means for the Future of Cannabis
The Wageningen research sits at the intersection of evolutionary biology, pharmacology, and agricultural biotechnology. Its implications reach beyond academic curiosity into several practical domains.
For cannabis breeders, the identification of ancestral enzyme sequences provides new genetic tools for developing cultivars with novel cannabinoid profiles. Instead of being limited to THC and CBD as primary targets, breeders may soon be able to create strains optimized for CBC, CBG, or custom combinations of multiple cannabinoids.
For pharmaceutical companies, the robustness of ancestral enzymes could accelerate the development of biosynthetic cannabinoid production — moving the industry beyond agricultural extraction toward precision fermentation. This would enable pharmaceutical-grade cannabinoid production at scale, with the consistency and purity that medical applications demand.
For consumers and patients, the research promises a future with more targeted, more diverse cannabis products. As the science of cannabinoid biosynthesis matures, the era of "THC percentage as the only metric that matters" may finally give way to a more sophisticated understanding of how the full spectrum of cannabinoids works together.
Pull-Quote Suggestions:
"Using a technique called ancestral sequence reconstruction, they analyzed DNA from modern cannabis plants to computationally infer the amino acid sequences of enzymes that existed millions of years ago."
"Over millions of years, each copy accumulated mutations that sharpened its specificity — one becoming THCA synthase, another becoming CBDA synthase, and a third becoming CBCA synthase."
"For centuries, humans have known that cannabis produces compounds powerful enough to alter consciousness, relieve pain, and reduce inflammation."
Why It Matters: Wageningen University scientists resurrected ancient cannabis enzymes to reveal how THC, CBD, and CBC evolved. The breakthrough could reshape medicinal cannabis.